These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20529296)

  • 21. Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.
    Jarosławski S; Toumi M
    BMC Health Serv Res; 2011 Oct; 11():259. PubMed ID: 21982545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach.
    Gavious A; Greenberg D; Hammerman A; Segev E
    Eur J Health Econ; 2014 Jun; 15(5):553-61. PubMed ID: 24326947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
    Morgan SG; Vogler S; Wagner AK
    Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk sharing in managed entry agreements-A review of the Swedish experience.
    Andersson E; Svensson J; Persson U; Lindgren P
    Health Policy; 2020 Apr; 124(4):404-410. PubMed ID: 32093981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical risk-sharing agreements.
    Gandjour A
    Pharmacoeconomics; 2009; 27(5):431-2. PubMed ID: 19586080
    [No Abstract]   [Full Text] [Related]  

  • 27. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
    Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
    Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
    Hammerman A; Feder-Bubis P; Greenberg D
    Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Risk-sharing scheme in Israel--Kuvan as an allegory].
    Abadi-Korek I; Shemer J
    Harefuah; 2012 Jun; 151(6):362-3, 377, 376. PubMed ID: 22991868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient access schemes in Asia-pacific markets: current experience and future potential.
    Lu CY; Lupton C; Rakowsky S; Babar ZU; Ross-Degnan D; Wagner AK
    J Pharm Policy Pract; 2015; 8(1):6. PubMed ID: 25815200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
    Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
    Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe.
    Barcina Lacosta T; Vulto AG; Turcu-Stiolica A; Huys I; Simoens S
    BioDrugs; 2022 Mar; 36(2):217-229. PubMed ID: 35303281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia.
    Reyes-Travé A; Guarga-Solé L; Roig-Izquierdo M; Alonso-Pérez E; Clopés-Estela A; Delgadillo-Duarte J
    Pharmacoeconomics; 2021 Sep; 39(9):973-982. PubMed ID: 34109568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey.
    Russo P; Carletto A; Németh G; Habl C
    Health Policy; 2021 Sep; 125(9):1140-1145. PubMed ID: 34253396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stakeholder views of managed entry agreements: A literature review of national studies.
    Thanimalai S; Choon WY; Lee KK
    Health Policy Open; 2021 Dec; 2():100032. PubMed ID: 37383516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate.
    Toumi M; Jarosławski S; Sawada T; Kornfeld Å
    Appl Health Econ Health Policy; 2017 Feb; 15(1):5-11. PubMed ID: 27581118
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.